Edition:
United States

Quest Diagnostics Inc (DGX.N)

DGX.N on New York Stock Exchange

101.86USD
19 Sep 2017
Change (% chg)

-- (--)
Prev Close
$101.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
235,038
52-wk High
$112.83
52-wk Low
$79.15

Latest Key Developments (Source: Significant Developments)

Quest Diagnostics says qtrly adjusted earnings per share $1.55
Tuesday, 25 Jul 2017 08:23am EDT 

July 25 (Reuters) - Quest Diagnostics Inc :Reports Q2 revenue of $1.94 billion.Reports Q2 revenue up 1.9 percent on a reported basis.Quest diagnostics reports second quarter 2017 financial results, raises 2017 financial outlook.Raises 2017 financial outlook.Quest diagnostics inc sees ‍2017 capital expenditures $250 million to $300 million​.Qtrly earnings per share $1.37.Quest diagnostics inc -2017 ‍reported diluted eps now expected to be between $4.90 and $5.00​.Qtrly adjusted earnings per share $1.55.Qtrly adjusted diluted eps excluding amortization expense now expected to be between $5.62 and $5.72​.Qtrly net revenues $1,943 million versus $1,906 million.Ccash provided by operations now expected to be approximately $1.2 billion for 2017​.Q2 earnings per share view $1.42 -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $5.57 -- Thomson Reuters I/B/E/S.Q2 revenue view $1.94 billion -- Thomson Reuters I/B/E/S.Sees fy 2017 revenues $7.69 billion to $7.74 billion.Fy2017 revenue view $7.69 billion -- Thomson Reuters I/B/E/S.  Full Article

Quest Diagnostics to acquire Cape Cod Healthcare outreach laboratory business
Tuesday, 27 Jun 2017 01:01pm EDT 

June 27 (Reuters) - Quest Diagnostics Inc :Quest Diagnostics announces intent to acquire Cape Cod Healthcare outreach laboratory business in Massachusetts.Quest Diagnostics Inc - signed a nonbinding letter of intent to acquire outreach laboratory services business of Cape Cod Healthcare.Quest Diagnostics Inc - financial terms were not disclosed..Quest Diagnostics Inc - acquisition is subject to review by Massachusetts health policy commission and completion of a definitive agreement.Quest Diagnostics Inc - upon approval by HPC, organizations expect to complete transaction by January 1, 2018.Quest Diagnostics Inc - CCHC's hospital-based laboratories and inpatient and outpatient services it provides are not included in transaction.Quest diagnostics inc - the two organizations also intend to explore opportunities to collaborate in population health and data analytics.  Full Article

Oxford Immunotec announces favorable claim construction ruling in patent infringement litigation
Thursday, 15 Jun 2017 04:05pm EDT 

June 15 (Reuters) - Oxford Immunotec Global Plc : :Oxford Immunotec announces favorable claim construction ruling in patent infringement litigation.Oxford Immunotec- favorable Markman claim construction ruling by judge in patent infringement lawsuit against Qiagen,Quest Diagnostics,Laboratory Corp.  Full Article

Quest Diagnostics to acquire two laboratory businesses in Lewisville, Texas
Monday, 12 Jun 2017 04:03pm EDT 

June 12 (Reuters) - Quest Diagnostics Inc :Quest diagnostics to form precision oncology center of excellence through acquisition of two texas laboratory businesses to serve oncologists nationwide.Quest diagnostics inc says additional terms were not disclosed..Quest diagnostics inc - transaction is expected to be completed in q3 of calendar year 2017.Quest diagnostics inc says has signed definitive agreements to acquire two laboratory businesses in lewisville, texas.  Full Article

Quest Diagnostics reports Q1 revenue of $1.9 bln
Thursday, 20 Apr 2017 06:45am EDT 

April 20 (Reuters) - Quest Diagnostics Inc :Reports Q1 revenue of $1.9 billion.Reports Q1 revenue up 1.9 percent on a reported basis.FY2017 earnings per share view $5.46 -- Thomson Reuters I/B/E/S.FY2017 revenue view $7.67 billion -- Thomson Reuters I/B/E/S.Q1 earnings per share view $1.18, revenue view $1.87 billion -- Thomson Reuters I/B/E/S.Quest diagnostics reports first quarter 2017 financial results, raises 2017 financial outlook.Quest diagnostics inc - 2017 reported diluted eps now expected to be between $4.73 and $4.88.Qtrly earnings per share $1.16.2017 adjusted diluted eps excluding amortization expense now expected to be between $5.45 and $5.60.Qtrly net revenues $1,899 million versus $1,863 million.Quest diagnostics inc sees 2017 capital expenditures $250 million - $300 million.Quest diagnostics inc sees 2017 revenue $7.64 billion - $7.72 billion.  Full Article

Vermillion say co, unit entered amendment No. 2 to testing, services agreement with Quest Diagnostics effective March 11, 2017
Monday, 13 Mar 2017 04:40pm EDT 

Vermillion Inc : Vermillion - co, unit entered amendment no. 2 to testing and services agreement with quest diagnostics incorporated effective March 11, 2017 .Vermillion Inc - primary purpose of amendment was to extend initial term of testing and services agreement from March 11, 2017 to March 11, 2018.  Full Article

Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis
Wednesday, 8 Feb 2017 08:00am EST 

Veracyte Inc : Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis through agreement with quest diagnostics . Says quest diagnostics is expected to begin offering test to its customers nationally in Q2 of 2017 . Says financial and other terms of agreement were not disclosed. .Physician clients of quest diagnostics will be able to order test on behalf of patients, refer patient specimens to co for genomic testing.  Full Article

Quest Diagnostics posts Q4 diluted EPS of $1.09 per share
Thursday, 26 Jan 2017 06:45am EST 

Quest Diagnostics Inc: Reports Q4 adjusted earnings per share $1.31 excluding items . Reports FY 2016 adjusted earnings per share $5.15 . Reports Q4 2016 revenue $1.86 billion . Reports Q4 2016 revenue up 0.7 percent . Quest diagnostics reports fourth quarter and full year 2016 financial results; provides guidance for full year 2017 . Q4 revenues of $1.86 billion, up 0.7% on a reported basis and up 1.9% on an equivalent basis versus 2015 . Quest diagnostics inc says full year 2017 reported diluted eps expected to be between $4.65 and $4.80 . Q4 diluted EPS of $1.09 on a reported basis . Fy2017 earnings per share view $5.45 -- Thomson Reuters I/B/E/S . Q4 diluted eps of $1.31 on an adjusted basis . Quest diagnostics Inc sees fy 2017 capital expenditures btwn $250 million- $300 million . Quest Diagnostics Inc sees fy 2017 revenues $7.64 billion- $7.72 billion . Fy2017 revenue view $7.66 billion -- Thomson Reuters I/B/E/S .Quest diagnostics inc sees fy 2017 diluted eps $4.65- $4.80.  Full Article

Quest Diagnostics launches hepatitis b virus quantitative test
Wednesday, 18 Jan 2017 08:00am EST 

Quest Diagnostics Inc :Launches hepatitis b virus quantitative test to help assess response to antiviral therapy.  Full Article

Oxford Immunotec announces favorable recommendation by the magistrate judge
Thursday, 1 Sep 2016 07:03am EDT 

Oxford Immunotec Global PLC : Oxford Immunotec announces favorable recommendation by the magistrate judge in patent infringement litigation . Says recommendation denying in substantial part defendants' motion to dismiss company's claims . Patent infringement lawsuit against Qiagen Inc, Quest Diagnostics Inc and Laboratory Corporation of America Holdings .Says recommendation should now "allow company to press forward with its case against three defendants".  Full Article

Quest to offer cholesterol testing without fasting requirement

Quest Diagnostics Inc said on Thursday it will begin using a more precise method of calculating levels of "bad" LDL cholesterol that no longer requires fasting prior to blood draw, a development likely to delight patients who previously had to refrain from eating for up to 12 hours before testing.